Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Gynecologic 3Breast 2Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 69Triple Negative Breast Neoplasms 32Ovarian Neoplasms 21Neoplasm Metastasis 10Prostatic Neoplasms 8Pancreatic Neoplasms 7Fanconi Anemia, Complementation Group D1 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Advanced Breast Cancer 4Recurrence 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Inflammatory Breast Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms, Castration-Resistant 1Primary Myelofibrosis 1Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian 1

Interventions

pembrolizumab 36Nivolumab 16Cyclophosphamide 12atezolizumab 8Docetaxel 8Magnetic Resonance Spectroscopy 7Paclitaxel 6Everolimus 6spartalizumab 5fludarabine 5durvalumab 5Specimen Handling 5Ipilimumab 5cabozantinib 4avelumab 4Trastuzumab 4Radiotherapy 4Radiosurgery 4Oxaliplatin 4Leucovorin 4temsirolimus 3pazopanib 3aldesleukin 3Taxes 3Sunitinib 3Psychiatric Rehabilitation 3Interleukin-2 3Immune Checkpoint Inhibitors 3Gemcitabine 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × olaparib × Breast × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05949424 2023-11-29

OPTI-DOSE

University Medical Center Groningen

Phase 4 Unknown
30 enrolled
BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡